Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00125333 · ClinicalTrials.gov registry record · Phase 1
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
A Phase 1 study, sponsored by Anesiva.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT00125333 is a Phase 1 study that has completed, run by Anesiva. The registered enrollment target is 75 participants.
The verdict
NCT00125333, a Phase 1 study, has completed, sponsored by Anesiva.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether this topical NF-kappaB Decoy candidate is safe in persons with atopic dermatitis. Preliminary evidence of efficacy (whether it is working) will also be evaluated.
Interventions
- DRUG NF-kappaB Decoy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00125333
The ClinicalTrials.gov registry entry for NCT00125333 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anesiva, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NF-kappaB Decoy is the first listed.
NCT00125333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00125333 about?
NCT00125333 is a clinical study titled "Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis". The purpose of this study is to determine whether this topical NF-kappaB Decoy candidate is safe in persons with atopic dermatitis. Preliminary evidence of efficacy (whether it is working) will also be evaluated.
What is the current status of trial NCT00125333?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2005-03. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00125333?
The interventions under investigation include: NF-kappaB Decoy (DRUG).
Who is sponsoring clinical trial NCT00125333?
This trial is sponsored by Anesiva, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.